Cargando…

Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver

BACKGROUND: Mice with humanized livers are important models to study drug toxicology testing, development of hepatitis virus treatments, and hepatocyte transplantation therapy. However, the huge difference between mouse and human in size and anatomy limited the application of humanized mice in inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Jilong, Yu, Dawei, Wang, Jing, Xu, Kai, Xu, Yanan, Sun, Renren, An, Peipei, Li, Chongyang, Feng, Guihai, Zhang, Ying, Dai, Xiangpeng, Zhao, Hongye, Wang, Zhengzhu, Han, Zhiqiang, Zhu, Haibo, Ding, Yuchun, You, Xiaoyan, Liu, Xueqin, Wu, Meng, Luo, Lin, Li, Ziyi, Yang, Yong-Guang, Hu, Zheng, Wei, Hong-jiang, Ge, Liangpeng, Hai, Tang, Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900390/
https://www.ncbi.nlm.nih.gov/pubmed/35255981
http://dx.doi.org/10.1186/s13578-022-00760-3
_version_ 1784664102698745856
author Ren, Jilong
Yu, Dawei
Wang, Jing
Xu, Kai
Xu, Yanan
Sun, Renren
An, Peipei
Li, Chongyang
Feng, Guihai
Zhang, Ying
Dai, Xiangpeng
Zhao, Hongye
Wang, Zhengzhu
Han, Zhiqiang
Zhu, Haibo
Ding, Yuchun
You, Xiaoyan
Liu, Xueqin
Wu, Meng
Luo, Lin
Li, Ziyi
Yang, Yong-Guang
Hu, Zheng
Wei, Hong-jiang
Ge, Liangpeng
Hai, Tang
Li, Wei
author_facet Ren, Jilong
Yu, Dawei
Wang, Jing
Xu, Kai
Xu, Yanan
Sun, Renren
An, Peipei
Li, Chongyang
Feng, Guihai
Zhang, Ying
Dai, Xiangpeng
Zhao, Hongye
Wang, Zhengzhu
Han, Zhiqiang
Zhu, Haibo
Ding, Yuchun
You, Xiaoyan
Liu, Xueqin
Wu, Meng
Luo, Lin
Li, Ziyi
Yang, Yong-Guang
Hu, Zheng
Wei, Hong-jiang
Ge, Liangpeng
Hai, Tang
Li, Wei
author_sort Ren, Jilong
collection PubMed
description BACKGROUND: Mice with humanized livers are important models to study drug toxicology testing, development of hepatitis virus treatments, and hepatocyte transplantation therapy. However, the huge difference between mouse and human in size and anatomy limited the application of humanized mice in investigating human diseases. Therefore, it is urgent to construct humanized livers in pigs to precisely investigate hepatocyte regeneration and human hepatocyte therapy. CRISPR/Cas9 system and somatic cell cloning technology were used to generate two pig models with FAH deficiency and exhibiting severe immunodeficiency (FAH/RAG1 and FAH/RAG1/IL2RG deficiency). Human primary hepatocytes were then successfully transplanted into the FG pig model and constructed two pigs with human liver. RESULTS: The constructed FAH/RAG1/IL2RG triple-knockout pig models were characterized by chronic liver injury and severe immunodeficiency. Importantly, the FG pigs transplanted with primary human hepatocytes produced human albumin in a time dependent manner as early as 1 week after transplantation. Furthermore, the colonization of human hepatocytes was confirmed by immunochemistry staining. CONCLUSIONS: We successfully generated pig models with severe immunodeficiency that could construct human liver tissues. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00760-3.
format Online
Article
Text
id pubmed-8900390
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89003902022-03-17 Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver Ren, Jilong Yu, Dawei Wang, Jing Xu, Kai Xu, Yanan Sun, Renren An, Peipei Li, Chongyang Feng, Guihai Zhang, Ying Dai, Xiangpeng Zhao, Hongye Wang, Zhengzhu Han, Zhiqiang Zhu, Haibo Ding, Yuchun You, Xiaoyan Liu, Xueqin Wu, Meng Luo, Lin Li, Ziyi Yang, Yong-Guang Hu, Zheng Wei, Hong-jiang Ge, Liangpeng Hai, Tang Li, Wei Cell Biosci Research BACKGROUND: Mice with humanized livers are important models to study drug toxicology testing, development of hepatitis virus treatments, and hepatocyte transplantation therapy. However, the huge difference between mouse and human in size and anatomy limited the application of humanized mice in investigating human diseases. Therefore, it is urgent to construct humanized livers in pigs to precisely investigate hepatocyte regeneration and human hepatocyte therapy. CRISPR/Cas9 system and somatic cell cloning technology were used to generate two pig models with FAH deficiency and exhibiting severe immunodeficiency (FAH/RAG1 and FAH/RAG1/IL2RG deficiency). Human primary hepatocytes were then successfully transplanted into the FG pig model and constructed two pigs with human liver. RESULTS: The constructed FAH/RAG1/IL2RG triple-knockout pig models were characterized by chronic liver injury and severe immunodeficiency. Importantly, the FG pigs transplanted with primary human hepatocytes produced human albumin in a time dependent manner as early as 1 week after transplantation. Furthermore, the colonization of human hepatocytes was confirmed by immunochemistry staining. CONCLUSIONS: We successfully generated pig models with severe immunodeficiency that could construct human liver tissues. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00760-3. BioMed Central 2022-03-07 /pmc/articles/PMC8900390/ /pubmed/35255981 http://dx.doi.org/10.1186/s13578-022-00760-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ren, Jilong
Yu, Dawei
Wang, Jing
Xu, Kai
Xu, Yanan
Sun, Renren
An, Peipei
Li, Chongyang
Feng, Guihai
Zhang, Ying
Dai, Xiangpeng
Zhao, Hongye
Wang, Zhengzhu
Han, Zhiqiang
Zhu, Haibo
Ding, Yuchun
You, Xiaoyan
Liu, Xueqin
Wu, Meng
Luo, Lin
Li, Ziyi
Yang, Yong-Guang
Hu, Zheng
Wei, Hong-jiang
Ge, Liangpeng
Hai, Tang
Li, Wei
Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver
title Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver
title_full Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver
title_fullStr Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver
title_full_unstemmed Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver
title_short Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver
title_sort generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900390/
https://www.ncbi.nlm.nih.gov/pubmed/35255981
http://dx.doi.org/10.1186/s13578-022-00760-3
work_keys_str_mv AT renjilong generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT yudawei generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT wangjing generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT xukai generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT xuyanan generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT sunrenren generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT anpeipei generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT lichongyang generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT fengguihai generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT zhangying generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT daixiangpeng generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT zhaohongye generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT wangzhengzhu generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT hanzhiqiang generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT zhuhaibo generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT dingyuchun generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT youxiaoyan generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT liuxueqin generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT wumeng generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT luolin generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT liziyi generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT yangyongguang generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT huzheng generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT weihongjiang generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT geliangpeng generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT haitang generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver
AT liwei generationofimmunodeficientpigwithhereditarytyrosinemiatype1andtheirpreliminaryapplicationforhumanizedliver